Creating Value for Psoriasis Patients: Development of a Patient-Driven Outcome Set for Clinical Practice

    Niels Hilhorst, Elfie Deprez, Nanny van Geel, Deepak Balak, Isabelle Hoorens, Jo Lambert
    Image of study
    TLDR Patients with psoriasis ranked symptom control and treatment efficacy as most important for their care.
    The study aimed to develop a patient-driven outcome set for managing psoriasis, a chronic inflammatory skin disease that significantly impacts patients' quality of life. A systematic review was first conducted, resulting in 23 patient-relevant outcomes. These outcomes were then presented to 10 patients to verify their relevance, and subsequently ranked by 120 patients attending a psoriasis clinic. The most important outcomes identified by patients were symptom control, treatment efficacy, confidence in care, and control of disease, while the least important were comorbidity control, productivity, and cost of care. Two outcomes were excluded as they were deemed inappropriate. The study concluded with the creation of the first patient-driven outcome set for psoriasis management, which may serve as a benchmarking tool to appraise and improve care across centers and among individual healthcare providers.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 141 results

    Similar Research

    5 / 1000+ results
      Dermatology

      research Dermatology

      1 citations , February 2004
      Skin diseases are common and can significantly affect people's lives; better outcome measures and ethical clinical trials are needed to improve dermatology care.
      Abstracts

      research Abstracts

      3 citations , May 2018 in “Experimental Dermatology”
      Young HS patients often have other physical and mental health issues, and research on HS covers a wide range of topics including genetics, triggers, treatments, and the need for more data.
      Autoimmune Skin Disorders

      research Autoimmune Skin Disorders

      2 citations , January 2019
      The document concludes that autoimmune skin disorders are treated with corticosteroids and immunosuppressive drugs.